Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Post by Smokey1958on Mar 06, 2021 6:15pm
363 Views
Post# 32737233

Great Article on Specificity and Sensitivity.....

Great Article on Specificity and Sensitivity.....

.....and why the improvements to AcuVid were so important. Thanks again, YInvext1 for correcting my mistake. Actually when I went back and looked at the NR I found even more reason to be excited about AcuVid.

At 100% Specificity AcuVid can detect all those that are covid negative ....so in theory there would be no false negatives ie. you're sending someone back out onto the street who is infected.

At lower viral loads AcuVid has a sensitivity of 86%. That means it is possible to have false positives ....and one of the reasons rapid antigen tests have been slow getting ramped up. The solution to that problem has been to have individuals testing covid positive to have a PCR test for confirmation.

At very high viral loads AcuVid is also 100% sensitive ....at least in a lab setting.

Therefore, if testing provides the same results, AcuVid would be the first rapid point of care test to require only a saliva sample and would fall within the range (83% to 94%) of sensitivities for tests already approved. Inexpensive, accurate, fast and easy to acquire the sample.

https://www.siemens-healthineers.com/laboratory-diagnostics/assays-by-diseases-conditions/infectious-disease-assays/specificity-matters

<< Previous
Bullboard Posts
Next >>